Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness
1997; Wiley; Volume: 55; Issue: 1 Linguagem: Inglês
10.1002/(sici)1096-8652(199705)55
ISSN1096-8652
AutoresJason Todd Estrin, Patricia Ford, David H. Henry, Arthur P. Stradden, Bernard A. Mason,
Tópico(s)PARP inhibition in cancer therapy
ResumoAmerican Journal of HematologyVolume 55, Issue 1 p. 51-52 Letters and CorrespondenceFree Access Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness Jason Todd Estrin, Corresponding Author Jason Todd Estrin Department of Molecular Biology, Princeton University, Princeton, New JerseyDepartment of Molecular Biology, Princeton University, Princeton, New JerseySearch for more papers by this authorPatricia A. Ford, Patricia A. Ford Oncology Hematology Associates. The Graduate Hospital, Medical School of the University of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this authorDavid H. Henry, David H. Henry Oncology Hematology Associates. The Graduate Hospital, Medical School of the University of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this authorArthur P. Stradden, Arthur P. Stradden Oncology Hematology Associates. The Graduate Hospital, Medical School of the University of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this authorBernard A. Mason, Bernard A. Mason Oncology Hematology Associates. The Graduate Hospital, Medical School of the University of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this author Jason Todd Estrin, Corresponding Author Jason Todd Estrin Department of Molecular Biology, Princeton University, Princeton, New JerseyDepartment of Molecular Biology, Princeton University, Princeton, New JerseySearch for more papers by this authorPatricia A. Ford, Patricia A. Ford Oncology Hematology Associates. The Graduate Hospital, Medical School of the University of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this authorDavid H. Henry, David H. Henry Oncology Hematology Associates. The Graduate Hospital, Medical School of the University of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this authorArthur P. Stradden, Arthur P. Stradden Oncology Hematology Associates. The Graduate Hospital, Medical School of the University of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this authorBernard A. Mason, Bernard A. Mason Oncology Hematology Associates. The Graduate Hospital, Medical School of the University of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this author First published: 06 December 1998 https://doi.org/10.1002/(SICI)1096-8652(199705)55:1 3.0.CO;2-9Citations: 19AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Goldberg SL, Chan CSP, Dawkins FW, Mehlman TW, Schechter PG: Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukemia? N Engl J Med 322: 777–778, 1990. 10.1056/NEJM199003153221115 CASPubMedWeb of Science®Google Scholar 2 Ford PA, Henry PH. Using r-H-EPO in patients unwilling to accept blood transfusions. Erythropoiesis 7: 63–68, 1996. Google Scholar Citing Literature Volume55, Issue1May 1997Pages 51-52 ReferencesRelatedInformation
Referência(s)